WO2002020517A1 - A thiazolidinedione derivative and its use as antidiabetic - Google Patents
A thiazolidinedione derivative and its use as antidiabetic Download PDFInfo
- Publication number
- WO2002020517A1 WO2002020517A1 PCT/GB2001/003979 GB0103979W WO0220517A1 WO 2002020517 A1 WO2002020517 A1 WO 2002020517A1 GB 0103979 W GB0103979 W GB 0103979W WO 0220517 A1 WO0220517 A1 WO 0220517A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fumarate
- solvate
- accordance
- methyl
- ethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- This invention relates to a novel pharmaceutical, to a process for the preparation of the pharmaceutical and to the use of the pharmaceutical in medicine.
- European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having hypoglycaemic and hypolipidaemic activity.
- the compound of example 30 of EP 0,306,228 is 5-[4- [2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter also referred to as "Compound (I)").
- WO94/05659 discloses certain salts of the compounds of EP 0,306,228.
- the preferred salt of WO94/05659 is the maleic acid salt.
- Compound (I) forms a novel fumarate salt (hereinafter also referred to as the "Fumarate”) that is particularly stable and hence is suitable for bulk preparation and handling. ..
- the Fumarate also has a high melting point and possesses good bulk flow properties. The Fumarate is therefore surprisingly amenable to large scale pharmaceutical processing and especially to large scale milling.
- the novel salt can be prepared by an efficient, economic and reproducible process particularly suited to large-scale preparation.
- the novel Fumarate also has useful pharmaceutical properties and in particular it is indicated to be useful for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
- the present invention provides 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione fumarate salt or a solvate thereof.
- the Fumarate is a mono-Fumarate salt as formed from a 1 : 1 molar ratio of Compound (I) and fumaric acid.
- Mono Fumarate salts also optionally comprise another monovalent salting ion such as an alkali metal or ammonium cation, to provide a "mixed salt"
- the Fumarate provides an infrared spectrum substantially in accordance with Figure 1. In one favoured aspect, the Fumarate provides a Raman spectrum substantially in accordance with Figure 2.
- the Fumarate provides an X-Ray powder diffraction pattern (XRPD) substantially in accordance with Table 1 or Figure 3.
- the Fumarate provides a solid state 13 C NMR spectrum substantially in accordance with Figure 4.
- the Fumarate provides a melting point in the range of from 154 to 159 °C, such as 155 to 158°C, for example 157.4 °C .
- the invention provides 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione fumarate salt, characterised in that it provides:
- the present invention encompasses the Fumarate or a solvate thereof isolated in pure form or when admixed with other materials.
- the invention provides the Fumarate or solvate thereof in a solid pharmaceutically acceptable form, such as a solid dosage form, especially when adapted for oral administration.
- the invention also provides the Fumarate or solvate thereof in a pharmaceutically acceptable form, especially in bulk form, such form being particularly capable of being milled.
- the invention therefore also provides the Fumarate or solvate thereof in a milled form.
- the invention provides the Fumarate or solvate thereof in a pharmaceutically acceptable form, especially in bulk form, such form having good flow properties, especially good bulk flow properties
- a suitable solvate is a hydrate.
- the invention also provides a process for preparing the Fumarate or a solvate thereof, characterised in that 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (Compound (I)) or a salt therof, preferably dispersed or dissolved in a suitable solvent, is reacted with a source of fumarate ion and thereafter, if required, a solvate of the resulting Fumarate is prepared; and the Fumarate or a solvate thereof is recovered.
- Compound (I) 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
- a salt therof preferably dispersed or dissolved in a suitable solvent
- Compound (I) is used in the reaction, especially in a protonated form.
- a salt of Compound (I) is used in the reaction..
- Compound (I) is preferably present in a protonated form.
- a suitable reaction solvent is a nitrile for example acetonitrile, an ether such as tetrahydrofuran, an alkanolsuch as methanol, or a hydrocarbon, such as toluene, a ketone, such as acetone, an ester, such as ethyl acetate, or a halogenated hydrocarbon such as dichloromethane, or water, or an organic acid such as acetic acid; or a mixture thereof.
- a nitrile for example acetonitrile, an ether such as tetrahydrofuran, an alkanolsuch as methanol, or a hydrocarbon, such as toluene, a ketone, such as acetone, an ester, such as ethyl acetate, or a halogenated hydrocarbon such as dichloromethane, or water, or an organic acid such as acetic acid; or a mixture thereof.
- the source of fumarate ion is fumaric acid.
- the fumaric acid is preferably added in solution but can be added as a solid.
- Suitable solvents for the fumaric acid include, water, a nitrile such as acetonitrile, tetrahydrofuran, or a lower alcohol such as methanol or ethanol, or a mixture of solvents.
- An alternative source of fumarate ion for a salt of Compound (I) is provided by a base salt of fumaric acid for example ammonium fumarate, or the fumaric acid salt of an amine, for example ethylamine or diethylamine.
- the concentration of Compound (I) is preferably in the range 2 to 25% weight/volume, more preferably in the range 5 to 20%.
- the concentration of fumaric acid solutions are preferably in the range of 3 to 20% weight/volume.
- the reaction is usually carried out at ambient temperature or at an elevated temperature, for example at the reflux temperature of the solvent, although any convenient temperature that provides the required product may be employed.
- Solvates such as hydrates, of the Fumarate are prepared according to conventional procedures.
- Recovery of the required compound generally comprises crystallisation from an appropriate solvent, conveniently the reaction solvent, usually assisted by cooling.
- the Fumarate may be crystallised from water or a nitrile such as acetonitrile or tetrahydrofuran or a mixture thereof.
- An improved yield of the salt can be obtained by evaporation of some or all of the solvent or by crystallisation at elevated temperature followed by controlled cooling, optionally in stages. Careful control of precipitation temperature and seeding may be used to improve the reproducibility of the product form.
- Crystallisation can also be initiated by seeding with crystals of the Fumarate or a solvate thereof but this is not essential.
- the mono-Fumarate salt is a mixed salt comprising another monovalent salting ion, such as an alkali metal or ammonium cation
- the said salt is conveniently formed by reacting the mono-Fumarate with a solution of the chosen monovalent salting ion, for example a metal or ammonium ion
- Compound (I) is prepared according to known procedures, such as those disclosed in EP 0,306,228 and WO94/05659. The disclosures of EP 0,306,228 and WO94/05659 are incorporated herein by reference.
- Fumaric acid is a commercially available compound.
- T onsel is generally determined by Differential Scanning Calorimetry and has a meaning generally understood in the art, as for example expressed in Pharmaceutical Thermal Analysis, Techniques and Applications", Ford and Timmins, 1989 as "The temperature corresponding to the intersection of the pre-transition baseline with the extrapolated leading edge of the transition".
- good flow properties is suitably characterised by the said compound having a Hausner ratio of less than or equal to 1.5, especially of less than or equal to 1.25.
- Diabetes ratio is an art accepted term. When used herein the term 'prophylaxis of conditions associated with diabetes mellitus' includes the treatment of conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinaemia and gestational diabetes.
- Diabetes mellitus preferably means Type II diabetes mellitus.
- Conditions associated with diabetes include hyperglycaemia and insulin resistance and obesity. Further conditions associated with diabetes include hypertension, cardiovascular disease, especially atherosclerosis ⁇ certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders associated with over-eating, such as obesity and anorexia bulimia. Additional conditions associated with diabetes include polycystic ovarian syndrome and steroid induced insulin resistance.
- the complications of conditions associated with diabetes mellitus encompassed herein includes renal disease, especially renal disease associated with the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.
- the present invention accordingly provides the Fumarate or a solvate thereof for use as an active therapeutic substance.
- the present invention provides the Fumarate or a solvate thereof for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
- the Fumarate or a solvate thereof may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier. Suitable methods for formulating the Fumarate or a solvate thereof are generally those disclosed for Compound (I) in the above mentioned publications.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the Fumarate or a solvate thereof and a pharmaceutically acceptable carrier therefor.
- the Fumarate or a solvate thereof is normally administered in unit dosage form. ' ' ⁇ -
- the active compound may be administered by any suitable route but usually by the oral or parenteral routes.
- the compound will normally be employed in the form of a pharmaceutical composition in association with a pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.
- compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices.
- Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
- Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
- the tablets may be coated according to well known methods in the art.
- Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
- Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
- Suitable lubricants include, for example, magnesium stearate.
- Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
- Solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such, operations are, of course, conventional in the art.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl rj-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
- suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monoole
- fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
- the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
- Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
- compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
- the term 'pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
- the present invention further provides a method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which ' comprises administering an effective, non-toxic, amount of Fumarate or a solvate thereof to a human or non-human mammal in need thereof.
- compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Complete Drug Reference (London, The Pharmaceutical Press) and Harry's Cosmeticology (Leonard Hill Books).
- the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
- the present invention provides the use of Fumarate or a solvate thereof for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.
- the Fumarate or a solvate thereof may be taken in amounts so as to provide Compound (I) in suitable doses, such as those disclosed in EP 0,306,228, WO94/05659 or WO98/55122.
- the infrared absorption spectrum of a mineral oil dispersion of the product was obtained using a Nicolet 710 FT-IR spectrometer at 2 cm "1 resolution ( Figure 1). Data were digitised at 1 cm"l intervals. Bands were observed at: 2925, 2854, 1749, 1699, 1643, 1611, 1513, 1460, 1377, 1328, 1302, 1250, 1216, 1174, 1161, 1067, 1037, 1002, 973, 928, 885, 826, 767, 735, 714, 653, 617, 603, 557, 527, 507 cm "1 .
- the infrared spectrum of the solid product was recorded using a Perkin-Elmer Spectrum One FT-IR spectrometer fitted with a universal ATR accessory. Bands were observed at: 2932, 2765, 1749, 1693, 1642, 1611, 1541, 1513, 1468, 1411, 1382, 1357, 1328, 1303, 1270, 1250, 1235, 1216, 1174, 1161, 1146, 1066, 1036, 1002, 972, 928, 903, 884, 825, 786, 766, 736, 714 cm "1 .
- the X-Ray Powder Diffractogram pattern of the product ( Figure 3) was recorded using the following acquisition conditions: Tube anode: Cu, Generator tension: 40 kN, Generator current: 40 mA, Start angle: 2.0 °2 ⁇ , End angle: 35.0 °2 ⁇ , Step size: 0.02 °2 ⁇ , Time per step: 2.5 seconds.Characterisfic XRPD angles and relative intensities are recorded in Table 1.
- the solid-state NMR spectrum of the product ( Figure 4) was recorded on a Bruker AMX360 instrument operating at 90.55 MHz: The solid was packed into a 4 mm zirconia MAS rotor fitted with a Kel-F cap and rotor spun at eaJO kHz.
- the 13 C MAS spectrum was acquired by cross-polarisation from Hartmann-Hahn matched protons (CP contact time 3 ms, repetition time 15 s) and protons were decoupled during acquisition using a two-pulse phase modulated (TPPM) composite sequence.
- TPPM phase modulated
- the solid state stability of the drug substance was determined by storing approximately 1.0 g of the material in a glass bottle at a) 40°C / 75% Relative
- the material was assayed by HPLC for final content and degradation products in both cases. a) 40°C / 75%o RH: No significant degradation observed (HPLC assay 100% initial). b) 50°C: No significant degradation observed (HPLC assay 99% initial).
- the melting point of the Fumarate was determined according to the method described in the U.S. Pharmacopoeia, USP 23, 1995, ⁇ 741> "Melting range or temperature, Procedure for Class la", using a Buchi 545 melting point instrument. Melting Point: 157.4°C
- the T onse t of the drug substance was determined by Differential Scanning Calorimetry using a Perkin-Elmer DSC7 apparatus. ⁇ onset (10°C/minute, closed pan): 156 °C
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001284274A AU2001284274A1 (en) | 2000-09-07 | 2001-09-05 | A thiazolidinedione derivative and its use as antidiabetic |
JP2002525138A JP2004508367A (en) | 2000-09-07 | 2001-09-05 | Thiazolidinedione derivatives and their use as antidiabetic agents |
DK01963244T DK1315721T3 (en) | 2000-09-07 | 2001-09-05 | A thiazolidinedione derivative and its use as an antidiabetic agent |
EP01963244A EP1315721B1 (en) | 2000-09-07 | 2001-09-05 | A thiazolidinedione derivative and its use as antidiabetic |
KR1020037003415A KR100769007B1 (en) | 2000-09-07 | 2001-09-05 | A Thiazolidinedione Derivative and Its Use as Antidiabetic |
DE60124119T DE60124119T2 (en) | 2000-09-07 | 2001-09-05 | A THIAZOLIDE INDION DERIVATIVE AND ITS USE AS ANTIDIBLE |
US10/363,602 US20040014791A1 (en) | 2000-09-07 | 2001-09-05 | Thiazolidinedione derivative and its use as antidiabetic |
HK03107840A HK1057204A1 (en) | 2000-09-07 | 2003-10-30 | A thiazolidinedione derivative and its use as antidiabetic |
CY20071100008T CY1105903T1 (en) | 2000-09-07 | 2007-01-04 | A THIAZOLIDENEDIONE DERIVATIVE AND ITS USE AS AN ANTIDIABETIC |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0021978.2 | 2000-09-07 | ||
GBGB0021978.2A GB0021978D0 (en) | 2000-09-07 | 2000-09-07 | Novel pharmaceutical |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002020517A1 true WO2002020517A1 (en) | 2002-03-14 |
Family
ID=9899043
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2001/003979 WO2002020517A1 (en) | 2000-09-07 | 2001-09-05 | A thiazolidinedione derivative and its use as antidiabetic |
Country Status (15)
Country | Link |
---|---|
US (1) | US20040014791A1 (en) |
EP (1) | EP1315721B1 (en) |
JP (1) | JP2004508367A (en) |
KR (1) | KR100769007B1 (en) |
CN (2) | CN100415741C (en) |
AT (1) | ATE343574T1 (en) |
AU (1) | AU2001284274A1 (en) |
CY (1) | CY1105903T1 (en) |
DE (1) | DE60124119T2 (en) |
DK (1) | DK1315721T3 (en) |
ES (1) | ES2272528T3 (en) |
GB (1) | GB0021978D0 (en) |
HK (1) | HK1057204A1 (en) |
PT (1) | PT1315721E (en) |
WO (1) | WO2002020517A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39384E1 (en) | 1993-09-01 | 2006-11-07 | Smithkline Beecham P.L.C. | Substituted thiazolidinedione derivatives |
WO2007009799A1 (en) * | 2005-07-22 | 2007-01-25 | Ratiopharm Gmbh | Amino acid salts of rosiglitazone |
DE102009053562A1 (en) | 2009-11-18 | 2011-05-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition, useful for treating diabetes mellitus type 2 in a combination therapy with other antidiabetic agent, comprises rosiglitazone succinate as an active agent |
KR20140113689A (en) * | 2011-12-19 | 2014-09-24 | 아레스 트레이딩 에스.에이. | Pharmaceutical compositions comprising glitazones and nrf2 activators |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435741B2 (en) * | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0306228A1 (en) | 1987-09-04 | 1989-03-08 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
WO1994005659A1 (en) | 1992-09-05 | 1994-03-17 | Smithkline Beecham Plc | Substituted thiazolidinedione derivatives |
WO1998055122A1 (en) | 1997-06-05 | 1998-12-10 | Smithkline Beecham Plc | Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
WO1999031094A1 (en) * | 1997-12-16 | 1999-06-24 | Smithkline Beecham Plc | Hydrate of 5-[4-[2- (n-methyl-n- (2-pyridil)amino) ethoxy]benzyl] thiazolidine-2, 4-dione maleic acid salt |
WO1999031095A1 (en) * | 1997-12-16 | 1999-06-24 | Smithkline Beecham Plc | 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
WO1999031093A1 (en) * | 1997-12-16 | 1999-06-24 | Smithkline Beecham Plc | Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use |
WO2000000195A1 (en) * | 1998-06-30 | 2000-01-06 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for the treatment of diabetes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5741803A (en) * | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
-
2000
- 2000-09-07 GB GBGB0021978.2A patent/GB0021978D0/en not_active Ceased
-
2001
- 2001-09-05 CN CNB2005101285907A patent/CN100415741C/en not_active Expired - Fee Related
- 2001-09-05 EP EP01963244A patent/EP1315721B1/en not_active Expired - Lifetime
- 2001-09-05 AT AT01963244T patent/ATE343574T1/en not_active IP Right Cessation
- 2001-09-05 ES ES01963244T patent/ES2272528T3/en not_active Expired - Lifetime
- 2001-09-05 DE DE60124119T patent/DE60124119T2/en not_active Expired - Fee Related
- 2001-09-05 KR KR1020037003415A patent/KR100769007B1/en not_active IP Right Cessation
- 2001-09-05 AU AU2001284274A patent/AU2001284274A1/en not_active Abandoned
- 2001-09-05 WO PCT/GB2001/003979 patent/WO2002020517A1/en active IP Right Grant
- 2001-09-05 PT PT01963244T patent/PT1315721E/en unknown
- 2001-09-05 US US10/363,602 patent/US20040014791A1/en not_active Abandoned
- 2001-09-05 JP JP2002525138A patent/JP2004508367A/en not_active Withdrawn
- 2001-09-05 DK DK01963244T patent/DK1315721T3/en active
- 2001-09-05 CN CNA018180310A patent/CN1471530A/en active Pending
-
2003
- 2003-10-30 HK HK03107840A patent/HK1057204A1/en not_active IP Right Cessation
-
2007
- 2007-01-04 CY CY20071100008T patent/CY1105903T1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0306228A1 (en) | 1987-09-04 | 1989-03-08 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
WO1994005659A1 (en) | 1992-09-05 | 1994-03-17 | Smithkline Beecham Plc | Substituted thiazolidinedione derivatives |
WO1998055122A1 (en) | 1997-06-05 | 1998-12-10 | Smithkline Beecham Plc | Composition comprising 5-[4-[2-(n-methyl-n-2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
WO1999031094A1 (en) * | 1997-12-16 | 1999-06-24 | Smithkline Beecham Plc | Hydrate of 5-[4-[2- (n-methyl-n- (2-pyridil)amino) ethoxy]benzyl] thiazolidine-2, 4-dione maleic acid salt |
WO1999031095A1 (en) * | 1997-12-16 | 1999-06-24 | Smithkline Beecham Plc | 5-[4-[2- (n-methyl-n- (2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical |
WO1999031093A1 (en) * | 1997-12-16 | 1999-06-24 | Smithkline Beecham Plc | Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use |
WO2000000195A1 (en) * | 1998-06-30 | 2000-01-06 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for the treatment of diabetes |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39384E1 (en) | 1993-09-01 | 2006-11-07 | Smithkline Beecham P.L.C. | Substituted thiazolidinedione derivatives |
WO2007009799A1 (en) * | 2005-07-22 | 2007-01-25 | Ratiopharm Gmbh | Amino acid salts of rosiglitazone |
EA012594B1 (en) * | 2005-07-22 | 2009-10-30 | Рациофарм Гмбх | Amino acid salts of rosiglitazone |
DE102009053562A1 (en) | 2009-11-18 | 2011-05-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition, useful for treating diabetes mellitus type 2 in a combination therapy with other antidiabetic agent, comprises rosiglitazone succinate as an active agent |
KR20140113689A (en) * | 2011-12-19 | 2014-09-24 | 아레스 트레이딩 에스.에이. | Pharmaceutical compositions comprising glitazones and nrf2 activators |
EP2793876A1 (en) * | 2011-12-19 | 2014-10-29 | Ares Trading S.A. | Pharmaceutical compositions comprising glitazones and nrf2 activators |
US10426763B2 (en) | 2011-12-19 | 2019-10-01 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and NRF2 activators |
KR102188487B1 (en) | 2011-12-19 | 2020-12-09 | 뵈른 콜린 카르스 | Pharmaceutical compositions comprising glitazones and nrf2 activators |
US11484530B2 (en) | 2011-12-19 | 2022-11-01 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising the PPAR agonist INT-131 and Nrf2 activators |
EP2793876B1 (en) * | 2011-12-19 | 2023-10-04 | Kahrs, Bjoern Colin | Pharmaceutical compositions comprising glitazones and nrf2 activators |
Also Published As
Publication number | Publication date |
---|---|
US20040014791A1 (en) | 2004-01-22 |
EP1315721B1 (en) | 2006-10-25 |
JP2004508367A (en) | 2004-03-18 |
CY1105903T1 (en) | 2011-02-02 |
ES2272528T3 (en) | 2007-05-01 |
KR100769007B1 (en) | 2007-10-22 |
AU2001284274A1 (en) | 2002-03-22 |
GB0021978D0 (en) | 2000-10-25 |
DE60124119T2 (en) | 2007-05-16 |
DK1315721T3 (en) | 2007-02-19 |
CN1814599A (en) | 2006-08-09 |
HK1057204A1 (en) | 2004-03-19 |
CN1471530A (en) | 2004-01-28 |
ATE343574T1 (en) | 2006-11-15 |
CN100415741C (en) | 2008-09-03 |
PT1315721E (en) | 2007-01-31 |
DE60124119D1 (en) | 2006-12-07 |
KR20030031179A (en) | 2003-04-18 |
EP1315721A1 (en) | 2003-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1349855B1 (en) | 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione mesylate salt | |
EP1315723B1 (en) | The hydrochloride salt of 5[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
EP1446404B1 (en) | Rosiglitazone edisylates and their use as antidiabetics | |
AU2001276509A1 (en) | Tartrate salts of thiazolidinedione derivative | |
AU2001284284A1 (en) | The hydrochloride salt of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione | |
EP1315721B1 (en) | A thiazolidinedione derivative and its use as antidiabetic | |
EP1315724B1 (en) | A thiazolidinedione derivative and its use as antidiabetic | |
EP1305310B1 (en) | Tartrate salts of thiazolidinedione derivative | |
AU2001276508A1 (en) | Tartrate salts of thiazolidinedione derivative | |
EP1305311A1 (en) | Tartrate salt of thiazolidinedione derivative | |
WO2002020518A1 (en) | Thiazolidinone nitrate salt | |
EP1325000A1 (en) | A thiazolidinedione derivative and its use as antidiabetic | |
AU2001292034A1 (en) | A thiazolidinedione derivative and its use as antidiabetic | |
WO2003045946A1 (en) | 5-(4-(2-(n-methyl-n-(2-pyridil) amino) ethoxy) benzyl) thiazolidine-2, 4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 00300/DELNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002525138 Country of ref document: JP Ref document number: 1020037003415 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001963244 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037003415 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018180310 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2001963244 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10363602 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001963244 Country of ref document: EP |